AITRICS Raises $24 Mn to Supercharge its Medical AI Copilot & VitalCare Expansion

AITRICS will use its new $24M Series C funding to strengthen its AI-powered VitalCare platform, advance its clinician copilot V.Doc Pro, and push deeper into Asian and US markets through new subsidiaries and a collaboration with Mayo Clinic.

AITRICS, a Korean AI company, has raised 35 billion won ($24 million) to supercharge its medical AI copilot and expand VitalCare.

This latest investment round, which brings AITRICS’s total funding to 75 billion won ($51 million), drew strong support from existing investors Premier Partners, Hanriver Partners, Mirae Asset Venture Investment, and Shinyoung Securities-BSK Investment.

New investors KB Securities-Solidus Investment, SV Investment, and Mirae Asset Capital also came on board, signalling growing confidence in the company’s medical AI strategy.

AITRICS plans to channel the funding toward enhancing two of its core AI solutions.

AITRICS will use its new $24 Mn Series C funding to strengthen its AI-powered VitalCare platform, advance its clinician copilot V.Doc Pro, and push deeper into Asian and US markets through new subsidiaries and a collaboration with Mayo Clinic.

VitalCare, the company’s predictive analytics platform, helps clinicians detect patient deterioration earlier, while V.Doc Pro, an upcoming AI copilot powered by large language models, aims to support doctors with quicker, more accurate decision-making at the bedside.

AITRICS said the investment will accelerate improvements that make these tools faster, more intuitive, and more deeply embedded in everyday hospital workflows.

The company is also stepping up its international expansion. After setting up a subsidiary in Japan earlier this year, AITRICS plans to enter Vietnam and Hong Kong as part of its next phase of growth.

Beyond Asia, AITRICS is building its presence in the United States, where it established a subsidiary in late 2023. A key element of its US entry is its collaboration with Mayo Clinic, focused on developing new medical AI models and preparing for clinical trials of the company’s flagship solutions.

Reflecting on the round, CEO Kim Gwang-jun said investor confidence reinforces the company’s long-term vision. “Thanks to the continued trust and support of many investors, we have been able to reaffirm the company's direction and growth potential. The secured funds will be a great help in stably pursuing the company's mid- to long-term strategy and in strengthening the company's growth and competitiveness,” he said.

Stay tuned for more such updates on Digital Health News